Moneycontrol PRO
UPCOMING EVENT:Attend Traders Carnival Live, 3 days 12 sessions. Prices Increasing Soon Rs.1199/-, exclusive for Moneycontrol Pro subscribers. Register now!
you are here: HomeNewsBusiness

Suven Life gets patent for neuro-degenerative molecule

With this new patent, Suven has a total of 26 patents from New Zealand. The new patent is valid through 2033, Suven Life Sciences said in a BSE filing.

March 28, 2017 / 02:04 PM IST
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Drug firm Suven Life Sciences has received one product patent from New Zealand for its molecule to be used in the treatment of neuro-degenerative diseases.

With this new patent, Suven has a total of 26 patents from New Zealand. The new patent is valid through 2033, Suven Life Sciences said in a BSE filing.

"We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally," Suven CEO Venkat Jasti said.

These patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts, Suven Life Sciences said.

"Products out of these inventions may be out-licensed at various phases of clinical development like at phase I or phase II," it added.

Close

The new chemical entities are being developed for the treatment of cognitive impairment associated with disorders such as Alzheimer's disease, attention deficient hyperactivity disorder, Huntington's disease, major depressive disorder, Parkinson and Schizophrenia, Suven Life Sciences said.

Shares of Suven Life Sciences were trading 1.37 percent up at Rs 169.75 apiece on BSE.

stay updated

Get Daily News on your Browser
Sections
ISO 27001 - BSI Assurance Mark